Alveolar proteinosis syndrome: Pathogenesis, diagnosis, and management

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 5, 2009, Pages 491-498

  Huizar, Isham ^a   Kavuru, Mani S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Alveolar proteinosis; Autoimmune disease; GM CSF; PPAR g; Surfactant proteins and lipids; Whole lung lavage

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LUNG SURFACTANT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; HUMAN; IMMUNOCOMPETENT CELL; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; LUNG FUNCTION; LUNG LAVAGE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW;

B-LYMPHOCYTES; BIOPSY; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; DIAGNOSIS, DIFFERENTIAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES, ALVEOLAR; PULMONARY ALVEOLAR PROTEINOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68949167535     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832ea51c     Document Type: Review

References (71)

1. Ramirez J, Kieffer RF Jr, Ball WC Jr. Bronchopulmonary lavage in man. Ann Intern Med 1965; 63:819-828.
2. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123-1142.
3. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166:215-235.
4. Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 1994; 12 (Suppl 1):173-182.
5. Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481-486.
6. Bonfield TL, Raychaudhuri B, Malur A, et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003; 285:L1132-L1136.
7. Seymour JF, Begley CG, Dirksen U, et al. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood 1998; 92:2657-2667.
8. Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1143-1148.
9. Thomassen MJ, Yi T, Raychaudhuri B, etal. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95:85-92.
10. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163:524-531.
11. Asamoto H, Kitaichi M, Nishimura K, et al. Primary pulmonary alveolar proteinosis: clinical observation of 68 patients in Japan. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33:835-845.
12. Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114:1357-1362.
13. Prakash UB, Barham SS, Carpenter HA, et al. Pulmonary alveolar phospho-lipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62:499-518.
14. Ioachimescu OC, Kavuru MS. Pulmonary alveolar proteinosis. Chron Respir Dis 2006; 3:149-159.
15. Murray JF, Nadel JA. Murray and Nadel's textbook of respiratory medicine. Philadelphia, PA: Saunders; 2005.
16. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349:2527-2539.
17. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752-762.
18. Akino T, Ohno K. Phospholipids of the lung in normal, toxic, and diseased states. Crit Rev Toxicol 1981; 9:201-274.
19. Bates SR, Fisher AB. Surfactant protein A is degraded by alveolar macro-phages. Am J Physiol 1996; 271 :L258-L266.
20. Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony- stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113:2547-2556.
21. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSFtiter predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105:342-350.
22. Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58:252-257.
23. BarnaBP, Malur A, Dalrymple H, etal. A novel 1,25-dihydroxyvitamin D-activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP). Autoimmunity 2009; 42:56-62.
24. Bonfield TL, Farver CF, Barna BP, et al. Peroxisome proliferator- activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003; 29:677-682.
25. Thomassen MJ, Barna BP, Malur AG, et al. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res 2007; 48:2762-2768.
26. Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant home-ostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002; 64:775-802.
27. Sergeeva A, Ono Y, Rios R, et al. High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease. Leukemia 2008; 22:783-790.
28. Han X, Uchida K, Jurickova I, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009; 136:1261-1263.
29. Uchiyama M, Nagao T, Hattori A, et al. Pulmonary alveolar proteinosis in a patient with Behcet's disease. Respirology 2009; 14:305-308.
30. Buechner HA, Ansari A. Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Dis Chest 1969; 55:274-278.
31. Dawkins SA, Gerhard H, Nevin M. Pulmonary alveolar proteinosis: a possible sequel of NO2 exposure. J Occup Med 1991; 33:638-641.
32. Keller CA, Frost A, CaglePT, et al. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium. Chest 1995; 108:277-280.
33. McCunney RJ, Godefroi R. Pulmonary alveolar proteinosis and cement dust: a case report. J Occup Med 1989; 31:233-237.
34. McDonald JW, Alvarez F, Keller CA. Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material. Chest 2000; 117:1813-1817.
35. Miller RR, Churg AM, Hutcheon M, et al. Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 1984; 130:312-315.
36. Oller AR, Kirkpatrick DT, Radovsky A, et al. Inhalation carcinogenicity study with nickel metal powder in Wistar rats. Toxicol Appl Pharmacol 2008; 233:262-275.
37. Xipell JM, Ham KN, Price CG, et al. Acute silicoproteinosis. Thorax 1977; 32:104-111.
38. Wardwell NR Jr, Miller R, Ware LB. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. Respirology 2006; 11:663-665.
39. Tredano M, van Elburg RM, Kaspers AG, et al. Compound SFTPB 1549C->GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency. Hum Mutat 1999; 14:502-509.
40. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93:1860-1863.
41. Brasch F, Griese M, Tredano M, etal. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24:30-39.
42. Nogee LM, Dunbar AE III, Wert S, etal. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest 2002; 121:20S-21S.
43. Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711-2716.
44. Notarangelo LD, Pessach I. Out of breath: GM-CSFRalpha mutations disrupt surfactant homeostasis. J Exp Med 2008; 205:2693-2697.
45. Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703-2710.
46. Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63:366-373.
47. Yokota T, Matsumura Y, Ban N, et al. Heterozygous ABCA3 mutation associated with nonfatal evolution of respiratory distress. Eur J Pediatr 2008; 167:691-693.
48. Ikegami M, Ueda T, Hull W, et al. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996; 270:L650-L658.
49. Latzin P, Tredano M, Wust Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39-44.
50. Bonfield TL, Barna BP, John N, et al. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun 2006; 26:37-41.
51. Bonfield TL, Thomassen MJ, FarverCF, etal. Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor. J Immunol 2008; 181:235-242.
52. Baldan A, Tarr P, Vales CS, et al. Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis. J Biol Chem 2006; 281:29401-29410.
53. Ghio AJ, Stonehuerner JG, Richards JH, et al. Iron homeostasis and oxidative stress in idiopathic pulmonary alveolar proteinosis: a case-control study. Respir Res 2008; 9:10.
54. Woischnik M, Bauer A, Aboutaam R, et al. Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Eur Respir J 2008; 31:1197-1204.
55. Lee KN, Levin DL, Webb WR, et al. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest 1997; 111:989-995.
56. Arcasoy SM, Lanken PN. Images in clinical medicine. Pulmonary alveolar proteinosis. N Engl J Med 2002; 347:2133.
57. Rubinstein I, Mullen JB, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited. Arch Intern Med 1988; 148: 813-816.
58. Frazier AA, Franks TJ, Cooke EO, et al. From the archives of the AFIP: pulmonary alveolar proteinosis. Radiographics 2008; 28:883-899.
59. Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000; 55:659-667.
60. JohkohT, Itoh H, Muller NL, et al. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999; 211:155-160.
61. Holbert JM, Costello P, Li W, et al. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001; 176:1287-1294.
62. Vrielynck S, Mamou-Mani T, Emond S, et al. Diagnostic value of high-resolution CT in the evaluation of chronic infiltrative lung disease in children. AJR Am J Roentgenol 2008; 191:914-920.
63. Robinson TE, Trapnell BC, Goris ML, etal. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842-848.
64. Ramirez J. Bronchopulmonary lavage. New techniques and observations. Dis Chest 1966; 50:581-588.
65. Rogers RM, Tantum KR. Bronchopulmonary lavage. A 'new' approach to old problems. Med Clin North Am 1970; 54:755-771.
66. Wasserman K, Blank N, Fletcher G. Lung lavage (alveolar washing) in alveolar proteinosis. Am J Med 1968; 44:611-61 7.
67. Kao D, Wasserman K, Costley D, et al. Advances in the treatment of pulmonary alveolar proteinosis. Am Rev Respir Dis 1975; 111:361-363.
68. Ben-Abraham R, Greenfeld A, Rozenman J, et al. Pulmonary alveolar proteinosis: step-by-step perioperative care of whole lung lavage procedure. Heart Lung 2002; 31:43-49.
69. Selecky PA, Wasserman K, Benfield JR, et al. The clinical and physiological effect of whole-lung lavage in pulmonary alveolar proteinosis: a ten-year experience. Ann Thorac Surg 1977; 24:451-461.
70. Rogers RM, Levin DC, Gray BA, etal. Physiologic effects of bronchopulmonary lavage in alveolar proteinosis. Am Rev Respir Dis 1978; 118:255-264.
71. Yamamoto H, Yamaguchi E, Agata H, et al. A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Pediatr Pulmonol 2008; 43:828-830.